Hologic, Inc. (NASDAQ:HOLX) Holdings Trimmed by Cetera Investment Advisers

Cetera Investment Advisers trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 20,247 shares of the medical equipment provider’s stock after selling 217 shares during the quarter. Cetera Investment Advisers’ holdings in Hologic were worth $1,503,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of HOLX. Innealta Capital LLC acquired a new stake in shares of Hologic during the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. bought a new stake in shares of Hologic during the first quarter valued at approximately $37,000. Sunbelt Securities Inc. acquired a new stake in Hologic in the 2nd quarter valued at $37,000. Cranbrook Wealth Management LLC acquired a new stake in Hologic in the 2nd quarter valued at $47,000. Finally, Mather Group LLC. acquired a new stake in Hologic in the 1st quarter valued at $48,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Hologic news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HOLX shares. Mizuho boosted their price objective on Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Evercore ISI increased their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Stephens reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $87.50.

Hologic Trading Up 0.0 %

Shares of HOLX opened at $81.66 on Wednesday. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67. The business’s fifty day moving average is $81.03 and its 200-day moving average is $77.64. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The firm has a market cap of $19.06 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 2.89 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the business posted $0.93 EPS. Equities analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.